PyrOjas - Home

WHO WE ARE

We build immune technologies to reprogram the body to remember cancer — and end it for good.

Pyrojas is a biotechnology company developing immune therapies that deliver durable control of cancer. Our lead platform, PyroCells, is a whole-cell vaccine engineered from the patient's own tumor to activate a broad T cell response against diverse antigens.
‍
Backed by the National Cancer Institute, Bristol Myers Squibb, venture capital, and a world-class team of scientists, clinical oncologists, and immunologists — including Nobel Laureate Dr. James Allison — we're advancing a new era of precision immunotherapy.

the problem

Cancer evolves — giving rise to relapse. Most therapies don't.

Even after treatment, many cancers return. Why? Tumors aren't uniform — they’re made up of diverse cell populations that evolve over time.

Targeted therapies miss variants. Immune evasion drives recurrence.

our solution

A vaccine built from your own cancer cells.

PyroCells is an autologous whole tumor cell vaccine.

It uses the patient’s entire tumor as the immunogen — no selection, no assumptions — activating a diversified immune response that recognizes heterogeneous cancer antigens and remembers what to fight.

High Immunogenicity

Most therapies aim at one or a select few tumor antigens.

We use the full tumor cell, capturing the complete antigenic landscape to overcome the heterogeneity of cancer.

Full antigenic coverage

Broad immune memory across clones

Activates CD4+ and CD8+ T cells

98% Efficiency

Early whole-cell vaccines failed due to weak adjuvants and low engineering efficiency.

PyroCells combines potent adjuvants with 98% non-viral engineering efficiency — compared to 35% in historical models.

98% non-viral engineering efficiency

Validated across tumor types

Fully automated and reproducible

Delivered Early

Checkpoint inhibitors changed the industry. So did better trial design.

We’re delivering PyroCells in the adjuvant setting — early, when immune systems can act.

Engineered in under 24 hours

Enables same-week immunization

Matches current clinical standards

In pre-clinical models, PyroCells achieved 100% disease control — preventing tumor growth and clearing established tumors.

⚠️ PyroCells has not yet entered human trials.

Backed by world-class institutions. Built for rapid translation.